Multivariate analysis on OS in patients receiving systemic therapy for MCL, adjusted for gender and MIPI
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Chemotherapy regimen* | |||
| Nordic MCL2 | — | — | — |
| CHOP | 1.080 | .73-1.59 | .698 |
| CHOP/cytarabine | .900 | .53-1.52 | .692 |
| FC | 1.018 | .61-1.70 | .945 |
| Chlorambucil | 1.167 | .73-1.85 | .514 |
| Bendamustine | 1.032 | .51-2.10 | .930 |
| Other regimens | 1.613 | .97-2.68 | .065 |
| Cytarabine | 1.202 | .62-2.33 | .585 |
| CVP | 2.827 | 1.68-4.76 | <.001 |
| Rituximab | .660 | .51-.85 | .001 |
| ASCT† | .553 | .37-.83 | .004 |
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Chemotherapy regimen* | |||
| Nordic MCL2 | — | — | — |
| CHOP | 1.080 | .73-1.59 | .698 |
| CHOP/cytarabine | .900 | .53-1.52 | .692 |
| FC | 1.018 | .61-1.70 | .945 |
| Chlorambucil | 1.167 | .73-1.85 | .514 |
| Bendamustine | 1.032 | .51-2.10 | .930 |
| Other regimens | 1.613 | .97-2.68 | .065 |
| Cytarabine | 1.202 | .62-2.33 | .585 |
| CVP | 2.827 | 1.68-4.76 | <.001 |
| Rituximab | .660 | .51-.85 | .001 |
| ASCT† | .553 | .37-.83 | .004 |